Electra Therapeutics (NASDAQ:ETRA) Stock: Insider Orbimed Advisors Llc Buys 20,000 Shares

Electra Therapeutics, Inc. (NASDAQ:ETRA) Director Orbimed Advisors Llc bought 20,000 shares of the stock in a transaction dated Monday, November 9th. The stock was purchased at an average price of $8.24 per share, with a total value of $164,800.00. Following the purchase, the director owned 5,234,578 shares in the company, valued at $43,132,922.72. This trade represents a 0.38% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Orbimed Advisors Llc also recently made the following trade(s):

• On Tuesday, November 10th, Orbimed Advisors Llc purchased 22,700 shares of Electra Therapeutics stock. The shares were purchased at an average price of $8.45 per share, for a total transaction of $191,815.00.
• On Friday, November 6th, Orbimed Advisors Llc purchased 49,416 shares of Electra Therapeutics stock. The stock was purchased at an average cost of $7.85 per share, for a total transaction of $387,915.60.
• On Thursday, November 5th, Orbimed Advisors Llc acquired 156,091 shares of Electra Therapeutics stock. The stock was purchased at an average price of $7.31 per share, with a total value of $1,141,025.21.
• On Wednesday, November 4th, Orbimed Advisors Llc acquired 71,367 shares of Electra Therapeutics stock. The shares were purchased at an average cost of $7.53 per share, with a total value of $537,393.51.
• On Tuesday, November 3rd, Orbimed Advisors Llc acquired 245,113 shares of Electra Therapeutics stock. The shares were purchased at an average cost of $7.86 per share, with a total value of $1,926,588.18.
• On Monday, September 21st, Orbimed Advisors Llc bought 1,333,333 shares of Electra Therapeutics stock. The shares were acquired at an average price of $15.00 per share, for a total transaction of $19,999,995.00.

Electra Therapeutics Stock Performance

Shares of ETRA stock traded down $0.23 during mid-day trading on Tuesday, reaching $7.99. 298,185 shares of the company’s stock traded hands, compared to its average volume of 376,388. Electra Therapeutics, Inc. has a 12 month low of $6.86 and a 12 month high of $15.50.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on ETRA shares. Zacks Research raised shares of Electra Therapeutics to a “hold” rating in a research note on Wednesday, October 14th. HC Wainwright began coverage on shares of Electra Therapeutics in a research note on Monday, October 26th. They set a “buy” rating and a $30.00 target price for the company. Jefferies Financial Group assumed coverage on shares of Electra Therapeutics in a research note on Tuesday, October 13th. They set a “buy” rating and a $32.00 target price for the company. JPMorgan Chase & Co. began coverage on shares of Electra Therapeutics in a report on Thursday, October 22nd. They set an “overweight” rating and a $36.00 target price for the company. Finally, Wall Street Zen raised Electra Therapeutics to a “hold” rating in a research report on Saturday, September 26th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Electra Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $33.50.

Electra Therapeutics Company Profile

Electra Therapeutics, Inc. (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function. Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.